Biogen Inc. (NASDAQ:BIIB) today announced new data underscoring the efficacy and safety of its broad, industry-leading portfolio of multiple sclerosis (MS) therapies. These data will be presented during MSVirtual2020, the eighth joint meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), which will be held virtually September 11-13, 2020.
“We at Biogen are proud of our commitment to addressing both the urgent and long-term challenges facing people living with MS,” said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen. “The data we are presenting at ACTRIMS-ECTRIMS highlight the improved outcomes that our broad MS portfolio has continued to provide for people with relapsing forms of MS, regardless of where they are in their treatment journey, as well as our ongoing investment in research and development to identify potentially effective drug candidates.”
New Phase 3 Data Further Characterize the Effectiveness and Patient-Reported GI Tolerability of VUMERITY® (diroximel fumarate)
New data from the VUMERITY Phase 3 clinical program further define the effectiveness and safety profile of Biogen’s latest oral fumarate therapy. Findings from the five-week EVOLVE-MS-2 study reinforce clinically meaningful improvements in patient-assessed gastrointestinal (GI) tolerability associated with VUMERITY treatment (n=253) compared to TECFIDERA® (dimethyl fumarate) (n=251), and support its impact on quality of life for people with relapsing MS. Study participants taking VUMERITY reported a lower likelihood of experiencing GI symptoms that interfered with daily activities or were associated with missed work, as well as less concomitant medication use to treat GI symptoms.
An exploratory analysis from the ongoing EVOLVE-MS-1 study assessed the effects of VUMERITY on brain volume change and other clinical measures in people with relapsing MS (n=365) treated for up to two years. Separate studies have shown brain volume loss may be associated with cognitive impairment, physical disability and reduced quality of life in people with MS.1,2 Data from EVOLVE-MS-1 show:
- The annual rate of brain volume change in study participants treated with VUMERITY for two years was similar to the rate observed in healthy individuals; and
- Approximately 90 percent of people treated with VUMERITY remained free from confirmed disability progression and around 84 percent were relapse-free at two years.
Also being presented at the meeting are final data from the Phase 3 ENDORSE study, which further demonstrate the sustained efficacy and well-characterized safety profile of TECFIDERA in patients followed for up to 13 years.
Real-World Data From Separate Analyses in the Relapsing MS Population Show Improved Outcomes With TYSABRI® (natalizumab), PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a)
Through MS PATHS (Partners Advancing Technology and Health Solutions), Biogen is collaborating with leading MS centers in Europe and the U.S. to generate standardized, high-quality data from a diverse, real-world MS patient population. To date, more than 17,000 patients have been enrolled in MS PATHS. Data being presented from treatment in the real-world setting support improved outcomes associated with TYSABRI, PLEGRIDY and AVONEX. Results from separate analyses of MS PATHS data reveal the following:
- In the first comparison of MS PATHS standardized magnetic resonance imaging (MRI) protocols, analyses of changes in brain MRI (occurring over a mean follow-up of 0.8 years) were compared during natalizumab treatment with extended interval dosing (EID; n=85) to the approved every-four-week (Q4W; n=569) dosing. The analysis reported no significant differences in the rates of new T2 lesions, T2 lesion volumes and brain atrophy. Differences in MRI scanners and acquisition protocols in clinical practice have made comparisons of brain MRI outcomes challenging. Multiple real-world studies have suggested the effectiveness of natalizumab EID is similar to the approved Q4W dosing.3-7 Biogen continues to evaluate the efficacy, safety and tolerability of natalizumab EID through the prospective NOVA trial (NCT03689972), and recently filed with regulatory authorities for a subcutaneous dosing formulation which, if approved, would allow for more options for TYSABRI administration.
- Treatment with TYSABRI was associated with greater improvements than Ocrevus® (ocrelizumab) in several quality of life domains according to the Neuro-QoL (Quality of Life in Neurological Disorders) assessment. In a subgroup analysis of matched patients treated with TYSABRI or Ocrevus, significant improvement was observed in nine of 12 Neuro-QoL domains in patients treated with TYSABRI (n=144) and in four of 12 domains in patients treated with Ocrevus (n=502). Overall, annualized rates of improvement were higher with TYSABRI than with Ocrevus and significant differences were observed in three domains: positive affect and well-being, satisfaction with social roles and activities and sleep disturbance.
- Clinical outcomes in people with MS aged 60 or older (n=286), compared to those under 60 (n=729), indicate that PLEGRIDY and AVONEX may provide real-world treatment benefits over two years in both age groups. Data show functional improvements in processing speed test (PST) and contrast sensitivity test (CST) over one year in both age groups. Additionally, a majority of participants in both age groups remained free from relapse over two years.
Data From a Phase 1 Study of BIIB091 Supports Continued Development for the Treatment of MS
Biogen also presented data from a Phase 1 study of BIIB091, an orally active selective, reversible (noncovalent), small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK). Data evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending oral doses in healthy adult participants. Selective BTK inhibition may be beneficial for the treatment of MS by preventing B-cell and myeloid cell activation without immune cell depletion.
Data Presentations Featured at ACTRIMS-ECTRIMS:
Note: All poster presentations from MSVirtual2020 will be made available online at 8 a.m. ET on Friday, September 11, 2020.
- Improved GI Tolerability With Diroximel Fumarate is Associated With Clinically Meaningful Benefits on Quality of Life Compared With Dimethyl Fumarate in EVOLVE-MS-2 (Poster 0214)
- Effects of Diroximel Fumarate on Brain Volume Change and Disability Progression in Adults With Relapsing-Remitting Multiple Sclerosis From EVOLVE-MS-1 (Poster P0205)
- Safety and Efficacy in Patients Treated With Dimethyl Fumarate and Followed for 13 Years: Final Results of ENDORSE (Platform FC02.05 – Sunday, September 13, 1:48-2:00 p.m. ET)
- No Difference in Radiologic Outcomes for Natalizumab Patients on Extended Interval Dosing Compared With Standard Interval Dosing in MS PATHS (Poster P0360)
- Impact of Natalizumab on Quality of Life in a Real-World Cohort of Patients With Multiple Sclerosis: Results from MS PATHS (Poster P1036)
- Characteristics and Clinical Outcomes of Older Patients With MS Treated With Peginterferon Beta-1a or Intramuscular Interferon Beta-1a in MS PATHS (Poster P0843)
- A Phase 1 Study of BIIB091, a Bruton’s Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants: Preliminary Results (Poster P0186)